Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

Michigan's Supreme Court reexamines rulings that may affect how the state's consumer protection laws apply to insulin pricing ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Eli Lilly (NYSE:LLY) has expanded its ongoing collaboration with Swiss biotech KeyBioscience in a bid to obtain global rights ...

Nordic Bioscience subsidiary KeyBioscience has announced an extension of its strategic partnership with Eli Lilly, focusing ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Drug giant Eli Lilly announced Thomas Fuchs as its first chief AI officer. Previously, Fuchs was director of the Hasso ...

The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target ...

Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,158.00. The company’s shares closed yesterday at $910.69.